XTALPI (02228) saw its stock price surge 6.07% in morning trading, currently trading at HK$10.48 with a turnover of HK$1.292 billion.

Recently, XTALPI announced that PEP08, a next-generation PRMT5 inhibitor discovered with its assistance for PharmaEngine, Inc., has achieved an important clinical development milestone. PEP08 has recently received clinical trial approvals from the Australian Human Research Ethics Committee (HREC), the Therapeutic Goods Administration (TGA), and Taiwan's Food and Drug Administration (TFDA), marking the imminent launch of Phase I clinical trials for the drug. Based on this progress, XTALPI has confirmed receipt of milestone payments for this project.

China Merchants Securities noted that XTALPI's AI drug discovery business commercialization is progressing steadily, with drug discovery business achieving a year-over-year growth rate of 615% in the first half of 2025. The company maintains long-term partnerships with leading global pharmaceutical companies including Pfizer and Johnson & Johnson. XTALPI completed a pipeline collaboration agreement with DoveTree worth a total of $5.99 billion and has received the agreed upfront payment of $51 million, contributing incremental revenue to performance. Through shared quantum physics computing, multimodal AI, and automated platforms, XTALPI has achieved cross-domain reuse of its technology platform, successfully expanding into multiple fields including new energy, agriculture, and industrial materials.